149 related articles for article (PubMed ID: 34189909)
1. Mechanism-Based Inactivation of Cytochrome P450 3A4 and 3A5 by the Fibroblast Growth Factor Receptor Inhibitor Erdafitinib.
Tang LWT; Teng JW; Koh SK; Zhou L; Go ML; Chan ECY
Chem Res Toxicol; 2021 Jul; 34(7):1800-1813. PubMed ID: 34189909
[TBL] [Abstract][Full Text] [Related]
2. Infigratinib Is a Reversible Inhibitor and Mechanism-Based Inactivator of Cytochrome P450 3A4.
Tang LWT; Teng JW; Verma RK; Koh SK; Zhou L; Go ML; Fan H; Chan ECY
Drug Metab Dispos; 2021 Sep; 49(9):856-868. PubMed ID: 34326139
[TBL] [Abstract][Full Text] [Related]
3. Direct and Sequential Bioactivation of Pemigatinib to Reactive Iminium Ion Intermediates Culminates in Mechanism-Based Inactivation of Cytochrome P450 3A.
Tang LWT; Wei W; Verma RK; Koh SK; Zhou L; Fan H; Chan ECY
Drug Metab Dispos; 2022 May; 50(5):529-540. PubMed ID: 35153194
[TBL] [Abstract][Full Text] [Related]
4. Differential Reversible and Irreversible Interactions between Benzbromarone and Human Cytochrome P450s 3A4 and 3A5.
Tang LWT; Verma RK; Yong RP; Li X; Wang L; Lin Q; Fan H; Chan ECY
Mol Pharmacol; 2021 Sep; 100(3):224-236. PubMed ID: 34210765
[TBL] [Abstract][Full Text] [Related]
5. Mechanism-Based Inactivation of Cytochrome P450 3A4 by Benzbromarone.
Tang LWT; Verma RK; Fan H; Chan ECY
Mol Pharmacol; 2021 Apr; 99(4):266-276. PubMed ID: 33436520
[TBL] [Abstract][Full Text] [Related]
6. Metabolic Activation of the Acrylamide Michael Acceptor Warhead in Futibatinib to an Epoxide Intermediate Engenders Covalent Inactivation of CYP3A.
Tang LWT; Fu J; Koh SK; Wu G; Zhou L; Chan ECY
Drug Metab Dispos; 2022 Jul; 50(7):931-941. PubMed ID: 35512804
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of Human Cytochrome P450 3A4 and 3A5 by Dronedarone and N-Desbutyl Dronedarone.
Hong Y; Chia YM; Yeo RH; Venkatesan G; Koh SK; Chai CL; Zhou L; Kojodjojo P; Chan EC
Mol Pharmacol; 2016 Jan; 89(1):1-13. PubMed ID: 26490246
[TBL] [Abstract][Full Text] [Related]
8. Identification of Infigratinib as a Potent Reversible Inhibitor and Mechanism-Based Inactivator of CYP2J2: Nascent Evidence for a Potential In Vivo Metabolic Drug-Drug Interaction with Rivaroxaban.
Tang LWT; Wu G; Chan ECY
J Pharmacol Exp Ther; 2022 Aug; 382(2):123-134. PubMed ID: 35640957
[TBL] [Abstract][Full Text] [Related]
9. Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib.
Takakusa H; Wahlin MD; Zhao C; Hanson KL; New LS; Chan EC; Nelson SD
Drug Metab Dispos; 2011 Jun; 39(6):1022-30. PubMed ID: 21363997
[TBL] [Abstract][Full Text] [Related]
10. Tofacitinib Is a Mechanism-Based Inactivator of Cytochrome P450 3A4.
Guo X; Li W; Li Q; Chen Y; Zhao G; Peng Y; Zheng J
Chem Res Toxicol; 2019 Sep; 32(9):1791-1800. PubMed ID: 31414593
[TBL] [Abstract][Full Text] [Related]
11. Meclizine, a pregnane X receptor agonist, is a direct inhibitor and mechanism-based inactivator of human cytochrome P450 3A.
Foo WY; Tay HY; Chan EC; Lau AJ
Biochem Pharmacol; 2015 Oct; 97(3):320-30. PubMed ID: 26239802
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of Lapatinib.
Towles JK; Clark RN; Wahlin MD; Uttamsingh V; Rettie AE; Jackson KD
Drug Metab Dispos; 2016 Oct; 44(10):1584-97. PubMed ID: 27450182
[TBL] [Abstract][Full Text] [Related]
13. NADPH-Independent Inactivation of CYP2B6 and NADPH-Dependent Inactivation of CYP3A4/5 by PBD: Potential Implication for Assessing Covalent Modulators for Time-Dependent Inhibition.
Kosaka M; Zhang D; Wong S; Yan Z
Drug Metab Dispos; 2020 Aug; 48(8):655-661. PubMed ID: 32482757
[TBL] [Abstract][Full Text] [Related]
14. Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs.
McConn DJ; Lin YS; Allen K; Kunze KL; Thummel KE
Drug Metab Dispos; 2004 Oct; 32(10):1083-91. PubMed ID: 15377640
[TBL] [Abstract][Full Text] [Related]
15. Difference in Mechanism-Based Inhibition of Cytochrome P450 3A4 and 3A5 by a Series of Fluoroquinolone Antibacterial Agents.
Watanabe A; Takakusa H; Kimura T; Inoue SI; Kusuhara H; Ando O
Drug Metab Dispos; 2017 Mar; 45(3):336-341. PubMed ID: 27974381
[TBL] [Abstract][Full Text] [Related]
16. Overcoming Time-Dependent Inhibition (TDI) of Cytochrome P450 3A4 (CYP3A4) Resulting from Bioactivation of a Fluoropyrimidine Moiety.
Mandal M; Mitra K; Grotz D; Lin X; Palamanda J; Kumari P; Buevich A; Caldwell JP; Chen X; Cox K; Favreau L; Hyde L; Kennedy ME; Kuvelkar R; Liu X; Mazzola RD; Parker E; Rindgen D; Sherer E; Wang H; Zhu Z; Stamford AW; Cumming JN
J Med Chem; 2018 Dec; 61(23):10700-10708. PubMed ID: 30388368
[TBL] [Abstract][Full Text] [Related]
17. Mechanistic Studies of Cytochrome P450 3A4 Time-Dependent Inhibition Using Two Cysteine-Targeting Electrophiles.
Barr JT; Wang Z; Min X; Wienkers HJ; Rock BM; Rock DA; Wienkers LC
Drug Metab Dispos; 2020 Jun; 48(6):508-514. PubMed ID: 32193357
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of cytochrome P450 (P450) 3A4 but not P450 3A5 by OSI-930, a thiophene-containing anticancer drug.
Lin HL; Zhang H; Medower C; Hollenberg PF; Johnson WW
Drug Metab Dispos; 2011 Feb; 39(2):345-50. PubMed ID: 21068193
[TBL] [Abstract][Full Text] [Related]
19. Prediction of the drug-drug interaction potential of the α1-acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib.
De Zwart L; Snoeys J; Jacobs F; Li LY; Poggesi I; Verboven P; Goris I; Scheers E; Wynant I; Monshouwer M; Mamidi RNVS
CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1107-1118. PubMed ID: 34273250
[TBL] [Abstract][Full Text] [Related]
20. Mechanism-based inactivation of cytochrome P450 3A4 by 17 alpha-ethynylestradiol: evidence for heme destruction and covalent binding to protein.
Lin HL; Kent UM; Hollenberg PF
J Pharmacol Exp Ther; 2002 Apr; 301(1):160-7. PubMed ID: 11907170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
